Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Portola Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Spectrum Pharmaceuticals and Portola Pharmaceuticals were two of the most active biotech stocks in the market on Tuesday. Spectrum reported its fourth quarter earnings as well as 2017 full year earnings and was bleeding in the red in after-hours trading. Portola saw some gains after announcing its chief executive would be attending two conferences this month.

RDI Initiates Coverage on:

Spectrum Pharmaceuticals, Inc.
https://rdinvesting.com/report/?ticker=SPPI

Portola Pharmaceuticals, Inc.
https://rdinvesting.com/report/?ticker=PTLA

Spectrum Pharmaceuticals, Inc. shares were falling significantly in after-hours trading on Tuesday after the company released its fourth quarter earnings report and full year earnings report for 2017. The company reported a loss of $28.6 million for the fourth quarter. The company said it had a loss of 29 cents a share and revenue of $28.6 million. For the full year, Spectrum reported a loss of $91.2 million or $1.07 per share. Revenue was $128.4 million. Looking ahead the company is expecting full year revenue in the range of $90 million to $110 million. The company’s Chief Executive Officer, Joe Turgeon. remarked, “2017 was a landmark year for Spectrum driven by advancements in our pipeline. Poziotinib has the potential to be a life-altering therapy for cancer patients with exon-20 insertion mutations. ROLONTIS gives Spectrum a near-term opportunity to compete in a blockbuster market. We expect several pipeline milestones in 2018 and we look forward to keeping you updated.” Poziotinib is a drug in development by Hanmi Pharmaceutical, Luye Pharma, and Spectrum Pharmaceuticals for various cancers. Shares of Spectrum have more than tripled in the last 12 months before losses in after-hours trading yesterday.

Access RDI’s Spectrum Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/report/?ticker=SPPI

Portola Pharmaceuticals, Inc. shares closed up 6.60% on almost 2.5 million shares traded. The stock saw big gains in yesterday’s trading session. The only significant news from the biopharma company was that its chief executive officer, Bill Lis, will be presenting at two conferences this month. Lis will be attending Cowen and Company’s 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston and then Oppenheimer’s 28th Annual Healthcare Conference on Tuesday, March 20, 2018, at 10:55 a.m. Eastern Time in New York. The company is developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases and has a medicine called Bevyxxa®. Bevyxxa is an oral, once-daily Factor Xa inhibitor that has been approved by the U.S. Food and Drug Administration in June 2017.

Access RDI’s Portola Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/report/?ticker=PTLA

Our Actionable Research on Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 492083